FGF2 and gastrointestinal stromal tumor: However, IM-treated GIST430 treated with anti-FGF-2 Abs demonstrated elevated levels (up to ~6 fold) of activated MAPK, suggesting that GIST cells might compensate for AKT inhibition through increased MAPK signaling.